Codexis, Inc. Overview
Pro stress-test →Codexis is a leading enzyme engineering company powering scalable, sustainable solutions for therapeutic development. With its proprietary CodeEvolver® platform and ECO Synthesis™ platform, the company creates manufacturing solutions delivering enzymes that outperform legacy methods across RNAi therapeutics, diagnostics, and small molecule manufacturing.
Strategic Profile
Pro stress-test →The company is navigating a complex transition moving toward full-service oligonucleotide manufacturing, backed by a crucial $37.8 million supply agreement with Merck. The company is actively shifting away from its legacy small molecule biocatalysis business to focus on the ligase and ECO Synthesis™ business lines, representing a high-risk, high-reward strategic repositioning.
Competitive Landscape
Pro stress-test →Codexis differentiates through methodical approach, rigorous process development, and integration of advanced screening technologies; its work in optimizing yield, purity, and process quality makes it a noteworthy player in the biotechnology landscape. Enzyme-powered processes drive measurable impact with fewer impurities, faster timelines, and reduced waste and energy use.
Industry Context
Codexis, Inc. operates in Biopharmaceutical Manufacturing / Synthetic Biology.
Key facts
Founded: 2002 · Headquarters: Redwood City, California · Employees: Unknown · Revenue: $0.064-0.068B · Market cap: $0.085B